The Daily Toke

April 03, 2026

# THC & Politics: Federal Legalization Moves Forward as Congress Fragments

Forty House Democrats have introduced the MORE Act to federally legalize cannabis, marking another push toward deschedule the plant from Schedule I—a classification it has held since Nixon's 1970 Controlled Substances Act, despite his own Shafer Commission recommending decriminalization over 50 years ago. This latest effort arrives alongside a flurry of other legislative proposals. The PREPARE ACT, introduced on a bipartisan basis in April 2025, calls on the attorney general to develop a comprehensive legalization plan. The States Reform Act has been refiled as a bipartisan alternative. Meanwhile, the 119th Congress (January 2025 to January 2027) is tracking nearly 1,500 cannabis-related bills across federal and state legislatures—a staggering volume that reflects just how fragmented the policy landscape has become.

The closest thing to a win in this session isn't legalization at all: it's the Veteran's Equal Access Act, a provision embedded in the MilCon-VA spending bill that would improve medical cannabis access for veterans. Both House and Senate versions have passed the provision, but it requires final reconciliation and the president's signature—and it would only last one year before needing renewal. 🚀 THIS IS COOL Veterans fighting PTSD, chronic pain, and service-related anxiety have reported significant relief using legal THC products in states where they're available. However, this incremental approach highlights a deeper problem: while Congress debates, veterans in states without legal programs face limited alternatives to prescription opioids and benzodiazepines, whose overdose deaths totaled 16,000+ in recent years—a stark contrast to cannabis's zero recorded overdose deaths in human history.

Behind the legislative gridlock sits a historic regulatory shift already underway. The DEA announced it will reclassify marijuana from Schedule I to Schedule III—the same category as ketamine and some anabolic steroids—recognizing the plant's medical uses and lower abuse potential compared to heroin and LSD. This followed President Biden's 2022 call for a review and his subsequent pardons of thousands convicted of simple possession. 💰 MONEY MOVES The reclassification doesn't legalize recreational use, but it clears a significant regulatory hurdle and signals that even conservative drug policy institutions now acknowledge the Schedule I classification was indefensible. Attorney General Merrick Garland's signature threw the full weight of the Justice Department behind the proposal, and once the White House Office of Management and Budget approves it, the DEA will open a formal public comment period.

States are moving faster than Congress. Maryland has an active dispensary network. Pennsylvania's Governor Josh Shapiro has now included adult-use legalization in his state budget proposal for three consecutive years, backed by a broad coalition including civil rights leaders and criminal justice reform advocates who understand the historical cost of prohibition. 🤔 THINK ABOUT IT For decades, cannabis enforcement disproportionately targeted communities of color—generating criminal records that blocked employment, housing, and education—while alcohol, which kills approximately 95,000 Americans annually, remained legal and culturally normalized. The contradiction is finally becoming impossible to ignore, even among lawmakers who once opposed reform.

The fragmentation reflects a genuine policy problem: federal prohibition creates chaos for states that have legalized, businesses operating in legal markets, and patients seeking medical access without federal interference. Marijuana Moment is tracking legislation across all 50 states and Congress with interactive maps and bill-by-bill analysis, showing concentrations of legalization, decriminalization, medical program, and expungement bills. 💰 MONEY MOVES Some states are generating "extraordinary economic activity" through regulated adult-use markets while simultaneously building pathways to employment and wealth creation in communities historically harmed by the war on drugs. Yet businesses still cannot access federal banking, cannot deduct ordinary business expenses on federal taxes, and operate under constant threat of federal prosecution—despite operating legally in their home states.

What happens next depends on whether Congress can move beyond incremental reforms. The MORE Act, the PREPARE ACT, and the States Reform Act all represent different visions: full legalization versus federally-managed transition plans versus state-by-state deference. The DEA's reclassification will proceed whether Congress acts or not, changing how the plant is studied and regulated at the federal level. Veterans will likely get expanded medical access through the appropriations process. But until someone reconciles these competing bills and brings one across the finish line with presidential signature, Americans will continue living in a patchwork where the same plant is medicine in one state and felony contraband in another—50 years after the government's own experts said prohibition was the wrong call.

April 03, 2026

# Hemp Ban Watch Briefing

Enforcement actions against cannabis operators continue to escalate globally, revealing stark contrasts in how different jurisdictions treat the plant and those who cultivate or distribute it. In the UK, Gary Youds has become something of a folk hero to legalization advocates after nearly two decades of repeatedly opening cannabis cafes in Liverpool, facing raids, jail time, and refusing to stop—a pattern that raises questions about whether criminalization actually achieves its stated goals or simply cycles people through the justice system. Meanwhile, across the Atlantic, the case of Ryan Richmond illustrates how federal authorities have adapted their enforcement strategy: when marijuana charges alone failed to secure a conviction, prosecutors pivoted to tax law, specifically Section 280E of the Internal Revenue Code, which prohibits cannabis businesses from deducting ordinary operating expenses. Richmond argues he may be the only American ever sent to prison primarily on the basis of pot-related tax violations—a prosecutorial approach that suggests enforcement isn't disappearing; it's simply evolving.

🤔 THINK ABOUT IT These cases raise a fundamental question about prohibition's effectiveness: if decades of enforcement haven't stopped Gary Youds from opening cafes, and prosecutors must resort to creative tax law to secure convictions against operators, what is the actual public health or safety outcome? The resources devoted to these cases—police raids, prosecutorial time, prison beds—represent a significant government expenditure in jurisdictions where cannabis remains illegal. 💰 MONEY MOVES Those same resources, redirected toward regulation and taxation in legalized markets, have generated billions in legitimate tax revenue and created licensed employment; Colorado alone has collected over $2 billion in cannabis tax revenue since legalization began.

The broader pattern suggests that hemp and cannabis enforcement is entering a new phase. Rather than broad prohibition, authorities are now targeting specific operators through alternative legal frameworks—tax codes, licensing requirements, and regulatory violations—while legalization continues to expand in pockets of North America and signals from global markets indicate shifting attitudes toward the plant itself. The fact that enforcement still occurs in some jurisdictions while thriving legal markets operate in others creates a fragmented landscape where the same product can be a felony in one location and a regulated commodity in another, often separated by a single state or national border.

What remains consistent across jurisdictions is the fundamental reality: 🤔 THINK ABOUT IT cannabis has never caused an overdose death in recorded human history, yet it remains Schedule I in the United States—the same classification as heroin—while alcohol, which kills approximately 95,000 Americans annually, remains legal and taxed. The gap between documented harm and legal status continues to widen as more jurisdictions move toward normalization, leaving operators, patients, and advocates in prohibition zones facing increasing legal jeopardy for involvement with a substance whose safety profile is well-established.

April 03, 2026

# THC IN SCIENCE: A Briefing

Cannabis policy and enforcement continue to reveal stark contradictions in how governments treat different substances—and different people. Gary Youds, a Liverpool activist sometimes called the UK's "Cannabis Martyr," has spent nearly two decades opening cannabis cafes, getting raided, getting jailed, and simply reopening again. His repeated arrests and incarcerations stand in contrast to the legal status of alcohol, which kills approximately 95,000 Americans annually, yet faces no Schedule I classification and no mandatory prison sentences for possession or distribution. 🤔 THINK ABOUT IT Britain keeps locking up a man for cannabis while legal alcohol consumption kills tens of thousands across the Atlantic each year—what does that tell us about drug policy priorities?

Meanwhile, in the United States, the tax code has become an unexpected weapon in cannabis enforcement. Ryan Richmond, potentially the only American ever imprisoned specifically for the marijuana tax, discovered that when federal prosecutors struggled to win convictions under drug charges, they pivoted to Section 280E of the Internal Revenue Code—a provision that prevents businesses in federally illegal industries from deducting ordinary business expenses. 💰 MONEY MOVES This legal strategy has effectively weaponized tax law to criminalize cannabis entrepreneurs in ways that don't apply to equally illegal enterprises, creating a documented pattern where cannabis operators face financial and criminal consequences unavailable as enforcement tools against other prohibited industries.

The broader science of THC continues to advance despite federal Schedule I restrictions that theoretically classify it as having no accepted medical use. Yet research facilities worldwide are conducting legitimate clinical trials on cannabinoid therapeutics, and state-level medical cannabis programs have generated real-world patient data on chronic pain, PTSD, and treatment-resistant conditions. 🚀 THIS IS COOL Veterans in particular have emerged as a population where THC and CBD demonstrate measurable clinical benefit for PTSD and chronic pain—conditions that traditional pharmaceutical options often fail to adequately address. When states restrict THC access, these patients frequently lose access to a therapeutic option with zero recorded overdose deaths in human history, a safety profile that cannot be claimed by the opioid medications that killed over 16,000 Americans in recent years.

The fundamental tension in cannabis science remains unresolved at the policy level: federal classification as Schedule I requires that a substance have no accepted medical use, yet state-licensed medical cannabis programs, published clinical research, and documented patient outcomes all contradict that classification standard. 💰 MONEY MOVES The federal restriction simultaneously blocks mainstream pharmaceutical research while creating a multi-billion-dollar unregulated market where consumers cannot access standardized, tested products through legal channels. The economic and public health costs of this contradiction accumulate annually, as does the evidence that the policy itself—not the plant—drives many of the documented harms.

Science does not operate in a vacuum, and neither does policy. The persistence of cannabis prohibition despite scientific evidence, documented safety records, and therapeutic applications reflects institutional momentum more than current evidence. Gary Youds opening another cafe tomorrow and Ryan Richmond's tax conviction both exist within a system designed 50 years ago when different information and different political priorities prevailed. The question facing regulators now is whether policy will eventually align with what the science has been showing: that cannabis is a plant with genuine therapeutic applications, a zero-overdose safety profile, and documented medical utility that warrants reconsideration of its legal status.

April 03, 2026

# Texas Cannabis Briefing

I cannot write this news briefing as requested because the articles you've provided contain no actual content. The article list includes only URLs, source names, and dates with empty snippets and full-article fields. Articles 1-7 have no titles or text. Articles 8-12 are missing titles, dates, and most content details. Only Articles 8 and 9 contain partial information (both about UK/federal cases unrelated to Texas), while Articles 10-12 appear to be stylesheet and plugin files rather than news articles.

To write an accurate, factual news briefing about Texas cannabis with the editorial standards you've outlined, I would need:

- Article titles - Publication dates - Complete article text or substantive snippets - Confirmed Texas cannabis-specific reporting (the provided articles reference the UK, federal cases, and general cannabis news—not Texas policy or developments)

Please provide complete article content, and I'll deliver the briefing immediately, starting with the news itself and using your inline tags naturally where the content warrants them.